Fine-tuning the properties of the thrombin binding aptamer through cyclization: Effect of the 5'-3' connecting linker on the aptamer stability and anticoagulant activity.
Anticoagulant activity
Biophysical characterization
G-quadruplex
Thrombin
Thrombin binding aptamer
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
18
07
2019
revised:
21
09
2019
accepted:
21
10
2019
pubmed:
9
11
2019
medline:
17
2
2021
entrez:
9
11
2019
Statut:
ppublish
Résumé
A small library of cyclic TBA analogues (named cycTBA I-IV), obtained by covalently connecting its 5'- and 3'-ends with flexible linkers, has been synthesized with the aim of improving its chemical and enzymatic stability, as well as its anticoagulant properties. Two chemical procedures have been exploited to achieve the desired cyclization, based on the oxime ligation method (providing cycTBA I and II) or on Cu(I)-assisted azide-alkyne cycloaddition (CuAAC) protocols (for cycTBA III and IV), leading to analogues containing circularizing linkers with different chemical nature and length, overall spanning from 22 to 48 atoms. The resulting cyclic TBAs have been characterized using a variety of biophysical methods (UV, CD, gel electrophoresis, SE-HPLC analyses) and then tested for their serum resistance and anticoagulant activity under in vitro experiments. A fine-tuning of the length and flexibility of the linker allowed identifying a cyclic analogue, cycTBA II, with improved anticoagulant activity, associated with a dramatically stabilized G-quadruplex structure (ΔT
Identifiants
pubmed: 31699393
pii: S0045-2068(19)31143-5
doi: 10.1016/j.bioorg.2019.103379
pii:
doi:
Substances chimiques
Anticoagulants
0
Aptamers, Nucleotide
0
thrombin aptamer
145563-68-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103379Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.